2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of the American …, 2022‏ - jacc.org
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Circulation, 2022‏ - ahajournals.org
Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022‏ - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial

TG Neilan, T Quinaglia, T Onoue, SS Mahmood… - Jama, 2023‏ - jamanetwork.com
Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical
data have suggested that use of atorvastatin may be associated with a reduction in cardiac …

The updated landscape of tumor microenvironment and drug repurposing

MZ **, WL ** - Signal transduction and targeted therapy, 2020‏ - nature.com
Accumulating evidence shows that cellular and acellular components in tumor
microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and …

[HTML][HTML] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

G Curigliano, D Lenihan, M Fradley, S Ganatra… - Annals of …, 2020‏ - Elsevier
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia

J Herrmann - Nature Reviews Cardiology, 2020‏ - nature.com
Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging

AN Linders, IB Dias, T López Fernández, CG Tocchetti… - npj Aging, 2024‏ - nature.com
The population of cancer survivors is rapidly increasing due to improving healthcare.
However, cancer therapies often have long-term side effects. One example is cancer therapy …

Cardiotoxicity of anthracyclines

D Cardinale, F Iacopo, CM Cipolla - Frontiers in cardiovascular …, 2020‏ - frontiersin.org
Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure …

R Pudil, C Mueller, J Čelutkienė… - European journal of …, 2020‏ - Wiley Online Library
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …